Syndax is ending development of Niktimvo in idiopathic pulmonary fibrosis after the therapy failed in a mid-stage trial, an outcome that further narrows the near-term pipeline for IPF and emphasizes the risk of late translational divergence. Meanwhile, a Bayesian meta-analysis re-examined desmopressin in brain-bleed patients on antiplatelet therapy, finding no evidence of outcome benefit and signals suggesting possible harm—supporting a more cautious stance on off-label hemostasis strategies in this subgroup. Together, the updates highlight the continuing churn in respiratory and acute care programs where endpoint alignment, patient selection, and safety signals are driving rapid readjustments.